Advertisement

PharmacoEconomics & Outcomes News

, Volume 834, Issue 1, pp 2–2 | Cite as

Acalabrutinib not cost effective in chronic lymphocytic leukaemia

Clinical study
  • 5 Downloads

Reference

  1. Vreman RA, et al. Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia. Applied Health Economics and Health Policy : 18 Jul 2019. Available from: URL: http://doi.org/10.1007/s40258-019-00496-1

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations